Immunocore reports Q2 2024 revenue growth of 32% driven by KIMMTRAK sales of $75.3 million

Immunocore Holdings plc

2024-Q2 EPS reported -$0.72 revenue$145,902,000

KIMMTRAK net revenues were $75.3 million in Q2 2024, up 32% year-over-year, driven by US growth and global expansion.
Registrational Phase 3 TEBE-AM trial for KIMMTRAK in cutaneous melanoma converted from Phase 2/3; enrollment completion expected in 1H 2026.
First patient randomized in Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma.
Cash and equivalents at $859.6 million; company plans to repay $50 million loan by end of 2024.
Net loss narrowed to $11.6 million from $17.0 million in prior year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.